Jacob S.  Van Naarden net worth and biography

Jacob Van Naarden Biography and Net Worth

Jake Van Naarden serves as senior vice president and chief executive officer of Loxo@Lilly. In this role, Jake oversees all aspects of oncology spanning discovery through commercial.

Jake joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. Following the acquisition, Jake played a key role in establishing the Loxo@Lilly research and development program.

In his earlier roles, Jake worked in various biotechnology investing, operational, and advisory capacities, including positions with HealthCor Management, Aisling Capital, and Goldman Sachs.

Jake received his A.B. degree in molecular biology from Princeton University.

How old is Jacob S. Van Naarden?

Van Naarden is currently 39 years old. There are 8 older executives and no younger executives at Eli Lilly and Company. The oldest executive at Eli Lilly and Company is Mr. Jeffrey N. Simmons, Senior VP & President of Elanco Animal Health, who is 57 years old. Learn More on Jacob S. Van Naarden's age.

How do I contact Jacob S. Van Naarden?

The corporate mailing address for Van Naarden and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Jacob S. Van Naarden's contact information.

Has Jacob S. Van Naarden been buying or selling shares of Eli Lilly and Company?

Jacob S. Van Naarden has not been actively trading shares of Eli Lilly and Company within the last three months. Learn More on Jacob S. Van Naarden's trading history.

Who are Eli Lilly and Company's active insiders?

Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (SVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.

Are insiders buying or selling shares of Eli Lilly and Company?

In the last year, insiders at the sold shares 31 times. They sold a total of 2,074,936 shares worth more than $21,628,352,978.48. The most recent insider tranaction occured on January, 31st when Major Shareholder Lilly Endowment Inc sold 78,573 shares worth more than $50,920,804.11. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.

Information on this page was last updated on 1/31/2024.

Jacob S. Van Naarden Insider Trading History at Eli Lilly and Company

See Full Table

Jacob S. Van Naarden Buying and Selling Activity at Eli Lilly and Company

This chart shows Mr. Jacob S. Van Naarden's buying and selling at Eli Lilly and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eli Lilly and Company Company Overview

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $726.31
Low: $722.07
High: $750.01

50 Day Range

MA: $763.96
Low: $726.31
High: $792.28

2 Week Range

Now: $726.31
Low: $369.76
High: $800.78

Volume

3,486,055 shs

Average Volume

2,202,924 shs

Market Capitalization

$690.11 billion

P/E Ratio

125.23

Dividend Yield

0.70%

Beta

0.34